Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | TKT | P29401 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11396782 | 0.84 | DHFR (0.54) | — | |
| SCHEMBL28182812 | 0.83 | LMNA (0.56) | LMNATKTKDM4EALDH1A1CYP1A2 | |
| SCHEMBL7607052 | 0.81 | LMNA (1.00) | LMNATKTKDM4EALDH1A1CYP1A2 | |
| SCHEMBL15177870 | 0.81 | LMNA (0.44) | LMNATKTKDM4EALDH1A1CYP1A2 | |
| SCHEMBL27140362 | 0.81 | LMNA (0.45) | LMNA | |
| SCHEMBL12346332 | 0.79 | LMNA (0.63) | LMNATKTKDM4EALDH1A1CYP1A2 | |
| SCHEMBL20292491 | 0.79 | LMNA (0.42) | LMNATKTKDM4EALDH1A1 | |
| SCHEMBL20292482 | 0.79 | LMNA (0.42) | LMNAKDM4EALDH1A1CYP1A2TSHR | |
| SCHEMBL18987265 | 0.76 | LMNA (0.65) | LMNATKTKDM4EALDH1A1CYP1A2 | |
| SCHEMBL23748348 | 0.75 | LMNA (0.63) | LMNATKTKDM4EALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101555547-B | Passivant for inhibiting iron and aluminium impurity acid split leaching of phosphorite and operation method thereof | UNIV SICHUAN | 2010-12-01 | — | — | CN | claimed |
| CN-101555547-A | Passivant for inhibiting iron and aluminium impurity acid split leaching of phosphorite and operation method thereof | UNIV SICHUAN (CN) | 2009-10-14 | — | — | CN | claimed |
| US-20180237358-A1 | RADIOISOTOPE 18F SUBSTITUTED THIAMINE, AND SYNTHESIS METHOD AND USE THEREOF | ZHONGSHAN HOSPITAL FUDAN UNIVERSITY (CN) | 2018-08-23 | — | — | US | disclosed |
| EP-3339308-A1 | RADIOISOTOPE FLUORINE-18 SUBSTITUTED THIAMINE, SYNTHESIS METHOD THEREFOR, AND APPLICATIONS THEREOF | Zhongshan Hospital Fudan University (CN) | 2018-06-27 | — | — | EP | disclosed |
| CN-105085509-B | Radio isotope fluorine 18 generation thiamine, synthetic method and application | 复旦大学附属中山医院 | 2018-02-23 | — | — | CN | disclosed |
| CN-105085509-A | Radioisotope 18F substituted thiamine as well as synthesis method and application of radioisotope 18F substituted thiamine | ZHONGSHAN HOSPITAL FUDAN UNIV | 2015-11-25 | — | — | CN | disclosed |
| CN-101555547-B | Passivant for inhibiting iron and aluminium impurity acid split leaching of phosphorite and operation method thereof | UNIV SICHUAN | 2010-12-01 | — | — | CN | disclosed |
| CN-1146561-C | Pyrimidine derivatives having antitumor activity | 盐野义制药株式会社 | 2004-04-21 | — | — | CN | disclosed |
| US-6420367-B1 | RAS GENE | SHIONOGO & CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| CN-1317003-A | Pyrimidine derivatives having antitumor activity | SHIONOGI & CO (JP) | 2001-10-10 | — | — | CN | disclosed |
| EP-1097933-A1 | PYRIMIDINE DERIVATIVES EXHIBITING ANTITUMOR ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2001-05-09 | — | — | EP | disclosed |
| US-3954756-A | Method for producing pyrimidine | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237358-A1 | RADIOISOTOPE 18F SUBSTITUTED THIAMINE, AND SYNTHESIS METHOD AND USE THEREOF | SLC19A2, SLC35E1, SLC46A1 | LMNA 2934/4885TKT 15/4885KDM4E 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.